The iCMLf is seeking collaborators to join the iCMLf Cure Consortium (iC3), a global, multidisciplinary initiative focused on achieving a cure for CML.

Background

Over the past two decades, tyrosine kinase inhibitors have transformed CML into a manageable disease. Yet for most patients, cure remains elusive. Nearly half of those who achieve deep molecular response relapse after stopping therapy, reflecting the persistence of leukemia stem cells and their supportive microenvironment. Lifelong treatment carries clinical, psychological, and economic burdens and remains inaccessible or unsustainable in many parts of the world. A cure, therefore, is not only a scientific goal, but a global equity imperative.

Scientific vision

The iC3 builds on landmark work already underway to move to the next phase: validating biomarkers, dissecting immune and microenvironmental mechanisms of persistence, and translating these discoveries into strategies that enable durable treatment-free remission.

To achieve this, global collaboration is essential. No single centre or country can capture the biological diversity, scale, or multidisciplinary expertise required to solve this challenge. Convened by the iCMLf, the iC3 provides a trusted international framework bringing together molecular and computational scientists, clinicians, immunologists, and patient advocates from across regions.

Call for collaborators

The iCMLf invites expressions of interest from prospective partners worldwide who wish to collaborate through:

• Data or tissue sample contribution
• Participation in thematic research teams
• Computational, modelling, or technical expertise
• Clinical translation, biomarker validation, or trial development
• Patient engagement and advocacy partnerships

Participation is governed by a clear Membership and Governance Charter, with transparent data access, authorship principles, and ethical oversight. Collaboration may be project-based or programmatic, with flexible levels of engagement.

Individuals interested in exploring collaboration are invited to contact info@cml-foundation.org to request the iC3 Collaboration Prospectus and Expression of Interest form, or to discuss potential involvement informally.

The iCMLf looks forward to working with colleagues worldwide who share a commitment to advancing cure-focused science - and toward a future in which CML is truly curable, everywhere.

iC3 Leadership Team:
Prof. Brian Druker | Prof. Ravi Bhatia | Prof. S. Tiong Ong | Prof. Tim Hughes | Nicola Evans (iCMLf)